
Hopes For UN Ocean Conference
The third UN Ocean Conference in France next month will focus on the conservation and sustainable use of marine resources.
Member states are expected to adopt a political declaration, ' Our Ocean, Our Future: United for Urgent Action ', highlighting a need for 'significant and accessible' funding.
Next week's One Ocean Science Congress (3-6 June) will provide a scientific foundation for the UN Ocean Conference (9-13 June).
The SMC asked experts about what they want to see from the UN Ocean Conference, and their plans at the Science Congress.
Linda Faulkner (Ngāti Rangi, Whanganui), Natural Sciences Commissioner for the NZ National Commission for UNESCO and member of the advisory board for the UN Decade of Ocean Science for Sustainable Development, comments:
'Aotearoa New Zealand is an island nation that sits within the world's largest and deepest ocean basin spanning subtropical to subpolar latitudes; is home to some of the world's most unique biodiversity; is the seabird capital of the world; and is a marine mammal hotspot. It is also the backdrop to a unique ancestral past steeped in a relationship with the ocean that is as vast and varied as Te Moananui-a-Kiwa – the Pacific Ocean.
'The NZ National Commission for UNESCO has been engaging with the UN Decade of Ocean Science for Sustainable Development since its inception, looking to bring a uniquely New Zealand perspective, contribution and value to the achievement of Sustainable Development Goal 14.
'As Natural Sciences Commissioner I'm delighted to be supporting and co-facilitating a global indigenous dialogue session of representatives who will be meeting at the UN Oceans Conference in June to explore the contribution indigenous knowledge, woven alongside modern science, can make to the future of the health and wellbeing of our oceans, and therefore our communities from the local to global scales. We'll be focussing on opportunities and actions in the final five years of the UN Ocean Decade, with a view to identifying what success looks like, and what legacy we'd like to see beyond the Decade.'
Conflict of interest statement: No conflicts of interest. Linda is also Pou Whakarae Te Hiringa Taiao – Chief Scientist Māori Environmental Research at NIWA but is not commenting in that role.
Simon Thrush, Professor of Marine Ecology, Institute of Marine Science, University of Auckland/Waipapa Taumata Rau, comments:
'Preliminary documentation for the conference recognises the urgent need to address the biodiversity and climate crisis, while gaining benefits from the Ocean. There is one ocean, and we all rely on it. The ocean is not too big to fail, and it is not too big to fix.
'These are not new issues, and evidence of worrying signs in the state of our ocean have been reported in all marine ecosystems. Critical to the success of action is recognition of the feedbacks between governance and ecosystem where the slow speed of management action can itself drive environmental tipping points.
'The conference can build on a rising swell of acknowledgement of the need to change. The G7 2030 Nature Compact (signed by G7 leaders) recognizes the importance of focus on nature positive actions and calls for urgent, system-wide change. With over half the world's GDP ($US 44,000,000,000) moderately or highly dependent on nature and its services, this conference needs to take the next step.'What I hope to see emerge from the conference is more than a commitment to change – it's rapid and transformative action to restore nature alongside nature-people relationships. Good things can happen. For example, the BBNJ treaty (2023) for the High Seas has progressed Marine Protected Areas beyond national boundaries.
'Transformative change needs to be just and inclusive and to show a vision of life-supporting futures for all. An expanded investment in marine science, especially in biodiversity hot spots and oceanic regions, is needed to close critical knowledge gaps.
'In Aotearoa-New Zealand we have dragged the chain for too long. I hope our nation transitions into an exemplar of positive actions for our Exclusive Economic Zone and the high seas – and becomes an agent of change to assist the large ocean states of the Pacific and Antarctica.'
Conflicts of interest: None declared.
Professor Conrad Pilditch, Director of the Institute of Marine Sciences at the University of Auckland, comments:
'The upcoming UN Ocean Congress in Nice will focus on supporting and implementing Sustainable Development Goal 14 – the conservation and sustainable use of the oceans. 'This focus is long overdue with many of the World's marine ecosystems including in New Zealand suffering from the impacts of global heating, ocean acidification, overfishing and pollutants. The ocean biodiversity and the climate crisis are linked and to improve ocean health we need to transition to an ecosystem-based management approach that recognises the inter-connections and dependencies among the ecological and social ecosystems. We also need to transition to a true-blue economy, one where our activities in the ocean enhance nature and not degrade it.
'My hope for the meeting outcomes is that we not only have a high level of ambition with measurable targets and timelines for reducing key stressors and greatly expanding marine protection, but this is followed by immediate action.
'It is a challenging time for ocean governance in the high seas with international rules-based order shifting and international cooperation facing challenges. However, there are reasons for hope with the BBNJ (2023) bucking the trend with States agreeing on the process for High Seas marine protected areas. I would also want to see expanded investment in ocean science to close critical knowledge gaps and provide a basis for new blue economies.'
No conflicts of interest.
Professor Trisia Farrelly, Senior Research Scientist, Cawthron Institute and Coordinator of Scientists' Coalition for an Effective Plastics Treaty, comments:
'I'm attending the 2025 UN Ocean Conference with the Scientists' Coalition for an Effective Plastics Treaty to champion a science-based, legally binding global agreement that addresses plastic pollution across its full life cycle.
'Our objective is to ensure the treaty is grounded in independent evidence, protects human and environmental health, and prioritises justice for frontline, fence line, and Indigenous communities, including those in the Pacific who are disproportionately impacted by plastic pollution.'
No conflicts of interest.
Dr Cath McLeod, Chief Science Officer, Cawthron Institute, comments:
'Cawthron Institute is attending the 2025 One Ocean Science Congress to share our insights and strengthen global collaboration on ocean health and sustainable food systems.
'We're proud to represent Aotearoa New Zealand's leadership in marine research and innovation at this critical international forum, with a particular focus on supporting Pacific-led science and elevating Indigenous knowledge. This is an important opportunity to build partnerships that support resilient ecosystems, climate adaptation, and blue economy growth across our region.'
No conflicts of interest.
Associate Professor Xavier Pochon, Molecular Surveillance Team Leader, Cawthron Institute and Science Leader for Citizens of the Sea, comments:
'It's a privilege to represent Cawthron and Citizens of the Sea at the 2025 UN Ocean Conference and the One Ocean Science Congress in France this June to amplify community voices in global ocean governance.
'Cawthron Institute co-founded Citizens of the Sea because we believe people must be at the heart of ocean protection — from scientists and fishers to youth and Indigenous leaders — and this is a vital opportunity to highlight citizen-led action, foster knowledge exchange, and promote ocean stewardship across all levels of society.'
No conflicts of interest.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Scoop
3 days ago
- Scoop
Dengue In The Pacific Region – Expert Q&A
Press Release – Science Media Centre The SMC asked experts about the current situation in the Pacific. The Cook Islands declared a dengue outbreak in Rarotonga last week. Other Pacific nations including Sāmoa, Tonga, and Fiji are also experiencing outbreaks. The SMC asked experts about the current situation in the Pacific. Dr Gregor Devine, Senior Director, Field Entomology at the World Mosquito Program, comments: What is the immediate threat posed by dengue in the wider Pacific region, and how is this changing? 'Dengue fever is the world's most prevalent disease spread by mosquitoes. Cases are increasing across the Western Pacific (e.g., Pacific Island Countries and Territories, Laos, Cambodia, Vietnam) and South East Asia (e.g., Bangladesh, Indonesia, Thailand, and Timor-Leste). All of these countries experienced significant dengue outbreaks in 2024 and 2025, and the general trend in cases globally is relentlessly upwards. 'These increases are fuelled by 1) climate change (increased temperatures encourage mosquito proliferation and shorten the time needed for viruses to replicate in their mosquito hosts), 2) increasing globalisation (and the increased movement of humans carrying the virus), 3) immunological naïveté, where human populations are being exposed to new dengue serotypes, and 4) the limited impact of existing control measures. 'According to the Pacific Syndromic Surveillance System, as of May 27th 2025, dengue cases are increasing or peaking in Fiji, Samoa, Tonga, Kiribati, and Cook Islands. There have been deaths reported from Fiji, Tonga and Samoa.' What hopes are currently on the horizon for new technologies or programmes to combat the disease? 'Current responses to dengue outbreaks largely involve the application of insecticides and the implementation of environmental 'clean-up' campaigns, but these have limited impacts. Moreover, resistance to insecticides is increasingly documented in the Pacific, and this further reduces the impact of conventional vector control. 'A safe, effective and sustainable solution exists. The Wolbachia method, developed by the non-profit World Mosquito Program, involves releasing mosquitoes infected with a bacteria that reduces their ability to transmit dengue. It has been proven to have a tremendous impact on dengue transmission around the world. Wolbachia releases have been piloted in Fiji, Vanuatu, Kiribati, and New Caledonia. Following six years of Wolbachia mosquito releases in New Caledonia, the project has been hailed a monumental success, and the French territory hasn't had a dengue epidemic since 2019. This year, releases will continue in Kiribati, and be adopted in Timor-Leste.' What is your biggest concern and/or is there anything you wish people understood better about the situation? 'The upward trend in dengue case numbers regionally will inevitably stress public health systems and impact family well-being (through both the health and economic costs of hospitalisation and the lost earnings of the sick). Sustainable ways to combat dengue, such as the Wolbachia method, are desperately needed. Vaccines are still years away from being universally affordable and applicable.' Conflict of interest statement: Greg Devine is the Senior Director of Field Entomology for the World Mosquito Program Dr Joan Ingram, Medical Advisor, Immunisation Advisory Centre, comments: What is the immediate threat posed by dengue in the Pacific region, and how is this changing? 'Dengue outbreaks are currently affecting Kiribati, Samoa, Fiji, Tonga and French Polynesia with the most cases being reported from Fiji, according to The Pacific Community (SPC). Case numbers are increasing in all of those areas, apart from in French Polynesia. There are four dengue serotypes – and both serotype 1 and serotype 2 are currently circulating. 'The Pacific Islands are vulnerable to dengue outbreaks as they have high levels of mosquitoes and dengue viruses can be introduced by infected people. 'Between 2012 and 2021, there were 69 outbreaks of dengue fever among the Pacific Islands. However, they are not unique in having dengue fever – dengue is common in many other regions including the Americas, Africa, the Middle East and Asia. 'Globally, dengue cases were at a very high level in 2024, particularly in South America. Cases increased almost 30-fold there between 2000 and 2024. Urbanisation, globalisation and climate change have contributed to this increase.' What is your biggest concern and is there anything you wish people understood better about the situation? 'Dengue is often a leading cause of fever in risk countries. Estimates are that around 6 in 1000 travellers spending a month in a risk area become unwell with dengue, with up to 30% of them being hospitalised. 'Dengue is spread by common biting mosquitoes (various Aedes species), which thrive where humans live. The main way to avoid dengue is mosquito bite avoidance. Aedes mosquitoes (unlike the malaria-transmitting Anopheles) are daytime feeders, with two peak times of biting activity in the day – 2 to 3 hours after dawn, and mid-to-late afternoon. However, they may feed all day indoors or on overcast days. 'People should regularly apply effective repellent as well as using light-coloured clothing to cover up. In addition, they should take steps to reduce mosquitoes indoors (such as screens on windows and doors), and in the environment by emptying any water-holding containers.' What hopes are currently on the horizon for new technologies or programmes to combat the disease? 'Qdenga, a dengue vaccine, is available in 30 countries overseas but not in New Zealand. It protects against dengue serotype 1 and 2 very well, especially in people who have had previous dengue. Protection against serotypes 3 and 4 is still being evaluated. 'An earlier dengue vaccine increased the risk of severe dengue in people who had not had dengue previously. It does not seem as though Qdenga does that, but it is still being monitored and most authorities prefer to administer it to people with past dengue infection although the guidelines differ. 'A new hope for the future is the use of Wolbachia-infected Aedes aegypti. Wolbachia infection blocks the transmission of the dengue virus from mosquitoes. Trials are ongoing with promising results.' No conflicts of interest. Dr Berlin Kafoa, Director, Public Health Division at The Pacific Community (SPC), comments: What is the immediate threat posed by dengue in the Pacific region, and how is this changing? ' 1. Increasing morbidity due to escalating dengue outbreaks reported across the Pacific region with circulation of multiple serotypes. 'Dengue is actively circulating in at least six Pacific Island Countries and Territories (PICTs), including Fiji (>8,000 cases, 4 deaths), Tonga (793 cases, 3 deaths), French Polynesia (>2,000 cases), Samoa (110 cases, 1 death), Cook Islands, and Kiribati. Multiple serotypes (DENV-1, DENV-2, DENV-3) are co-circulating, increasing the risk of severe dengue due to secondary infections in populations with partial immunity. ' 2. Changing epidemiology and vulnerable populations 'There is a growing incidence of severe dengue amongst children and youth with no prior dengue exposure. There are older adults coming from areas historically free of dengue. This suggests immunity gaps, but the lack of updated seroprevalence data limits precise risk profiling. ' 3. Climate and mobility as amplifiers 'Climate change and variability (e.g., rainfall, temperature) is expanding mosquito habitats and altering transmission regional and international travel and trade from endemic areas (e.g., Southeast Asia, South America) raises the risk of virus introduction.' What hopes are currently on the horizon for new technologies or programmes to combat the disease? ' 1. A need for collaboration across sectors, agencies, and countries. 'Through the Pacific Public Health Surveillance Network (PPHSN), we are working with WHO and allied members to support countries with preparedness, detection and response to dengue and other arboviral diseases. This includes: Rapid risk assessments and technical guidance Laboratory supplies and testing algorithms and Strengthening PCR testing capabilities in countries. Subtyping and WGS/Whole-Genome Sequencing via reference labs (e.g., VIDRL in Australia). Dissemination of risk communication messages through multiple channels and sharing of best practices in risk communication and community engagement ' 2. A need for predictive analytics and early warning 'We are exploring predictive algorithms that integrate climate data (e.g., rainfall, temperature), flight and mobility data, and historical outbreak and seroprevalence data. These tools aim to forecast outbreak risks and optimize vector control timing.' ' 3. Vector control capacity building to promote a One Health approach. 'The Pacific Vector Network (PVN) launched in 2023, a service arm of PPHSN, supports a coordinated response to control of vector-borne disease in the region; practical entomology training for PICTs; mosquito surveys, mapping, and surveillance; and provision of vector control equipment and insecticides.' ' 4. New tools being tested 'Other new tools being tested in the region include pilot testing of new technologies such as Sterile Insect Technique (SIT) in French Polynesia, and trials of Wolbachia introduction in Fiji, Vanuatu, New Caledonia, and Kiribati. For possible consideration, there is the introduction of dengue vaccines-contingent on availability of sero-prevalence data.' What is your biggest concern and/or is there anything you wish people understood better? 'The real risk of severe dengue is rising. Severe cases and fatalities are being reported, especially among youth. Dengue should not be dismissed as a mild illness, it can be life-threatening. 'There are gaps in immunity and surveillance. Many populations remain immunologically naive due to limited past exposure. Inadequate seroprevalence data and diagnostic capacity hinder targeted responses. 'There are changes in vector behaviours with possible increase in behaviours resistance to insecticides. 'Dengue is not the only arboviral threat which further complicates surveillance, diagnosis, and response efforts. Other threats include: Zika: Imported cases have been reported in the Pacific Rim (e.g., New Zealand from Fiji). Chikungunya: A major outbreak in La Réunion (339,000+ cases) and an imported case in Wallis and Futuna. Yellow fever: While not yet reported in the Pacific, the presence of Aedes vectors makes introduction a real risk 'There is a need to support the Pacific to acquire new technology for genomic surveillance. Genetic sequencing of dengue strains is essential to track virus movement and mutations across the region, but capacity remains limited. 'Dengue is no longer a seasonal or isolated threat in the Pacific; it is a regional health emergency shaped by climate, mobility, and historical vulnerabilities. Through a One Health multisector, multiagency and multi-country collaborative efforts with WHO, PIHOA and PPHSN partners, we are responding and building the tools and intelligence to predict, prepare and hopefully prevent the next wave.'


Scoop
3 days ago
- Scoop
Dengue In The Pacific Region – Expert Q&A
Press Release – Science Media Centre The SMC asked experts about the current situation in the Pacific. The Cook Islands declared a dengue outbreak in Rarotonga last week. Other Pacific nations including Sāmoa, Tonga, and Fiji are also experiencing outbreaks. The SMC asked experts about the current situation in the Pacific. Dr Gregor Devine, Senior Director, Field Entomology at the World Mosquito Program, comments: What is the immediate threat posed by dengue in the wider Pacific region, and how is this changing? 'Dengue fever is the world's most prevalent disease spread by mosquitoes. Cases are increasing across the Western Pacific (e.g., Pacific Island Countries and Territories, Laos, Cambodia, Vietnam) and South East Asia (e.g., Bangladesh, Indonesia, Thailand, and Timor-Leste). All of these countries experienced significant dengue outbreaks in 2024 and 2025, and the general trend in cases globally is relentlessly upwards. 'These increases are fuelled by 1) climate change (increased temperatures encourage mosquito proliferation and shorten the time needed for viruses to replicate in their mosquito hosts), 2) increasing globalisation (and the increased movement of humans carrying the virus), 3) immunological naïveté, where human populations are being exposed to new dengue serotypes, and 4) the limited impact of existing control measures. 'According to the Pacific Syndromic Surveillance System, as of May 27th 2025, dengue cases are increasing or peaking in Fiji, Samoa, Tonga, Kiribati, and Cook Islands. There have been deaths reported from Fiji, Tonga and Samoa.' What hopes are currently on the horizon for new technologies or programmes to combat the disease? 'Current responses to dengue outbreaks largely involve the application of insecticides and the implementation of environmental 'clean-up' campaigns, but these have limited impacts. Moreover, resistance to insecticides is increasingly documented in the Pacific, and this further reduces the impact of conventional vector control. 'A safe, effective and sustainable solution exists. The Wolbachia method, developed by the non-profit World Mosquito Program, involves releasing mosquitoes infected with a bacteria that reduces their ability to transmit dengue. It has been proven to have a tremendous impact on dengue transmission around the world. Wolbachia releases have been piloted in Fiji, Vanuatu, Kiribati, and New Caledonia. Following six years of Wolbachia mosquito releases in New Caledonia, the project has been hailed a monumental success, and the French territory hasn't had a dengue epidemic since 2019. This year, releases will continue in Kiribati, and be adopted in Timor-Leste.' What is your biggest concern and/or is there anything you wish people understood better about the situation? 'The upward trend in dengue case numbers regionally will inevitably stress public health systems and impact family well-being (through both the health and economic costs of hospitalisation and the lost earnings of the sick). Sustainable ways to combat dengue, such as the Wolbachia method, are desperately needed. Vaccines are still years away from being universally affordable and applicable.' Conflict of interest statement: Greg Devine is the Senior Director of Field Entomology for the World Mosquito Program Dr Joan Ingram, Medical Advisor, Immunisation Advisory Centre, comments: What is the immediate threat posed by dengue in the Pacific region, and how is this changing? 'Dengue outbreaks are currently affecting Kiribati, Samoa, Fiji, Tonga and French Polynesia with the most cases being reported from Fiji, according to The Pacific Community (SPC). Case numbers are increasing in all of those areas, apart from in French Polynesia. There are four dengue serotypes – and both serotype 1 and serotype 2 are currently circulating. 'The Pacific Islands are vulnerable to dengue outbreaks as they have high levels of mosquitoes and dengue viruses can be introduced by infected people. 'Between 2012 and 2021, there were 69 outbreaks of dengue fever among the Pacific Islands. However, they are not unique in having dengue fever – dengue is common in many other regions including the Americas, Africa, the Middle East and Asia. 'Globally, dengue cases were at a very high level in 2024, particularly in South America. Cases increased almost 30-fold there between 2000 and 2024. Urbanisation, globalisation and climate change have contributed to this increase.' What is your biggest concern and is there anything you wish people understood better about the situation? 'Dengue is often a leading cause of fever in risk countries. Estimates are that around 6 in 1000 travellers spending a month in a risk area become unwell with dengue, with up to 30% of them being hospitalised. 'Dengue is spread by common biting mosquitoes (various Aedes species), which thrive where humans live. The main way to avoid dengue is mosquito bite avoidance. Aedes mosquitoes (unlike the malaria-transmitting Anopheles) are daytime feeders, with two peak times of biting activity in the day – 2 to 3 hours after dawn, and mid-to-late afternoon. However, they may feed all day indoors or on overcast days. 'People should regularly apply effective repellent as well as using light-coloured clothing to cover up. In addition, they should take steps to reduce mosquitoes indoors (such as screens on windows and doors), and in the environment by emptying any water-holding containers.' What hopes are currently on the horizon for new technologies or programmes to combat the disease? 'Qdenga, a dengue vaccine, is available in 30 countries overseas but not in New Zealand. It protects against dengue serotype 1 and 2 very well, especially in people who have had previous dengue. Protection against serotypes 3 and 4 is still being evaluated. 'An earlier dengue vaccine increased the risk of severe dengue in people who had not had dengue previously. It does not seem as though Qdenga does that, but it is still being monitored and most authorities prefer to administer it to people with past dengue infection although the guidelines differ. 'A new hope for the future is the use of Wolbachia-infected Aedes aegypti. Wolbachia infection blocks the transmission of the dengue virus from mosquitoes. Trials are ongoing with promising results.' No conflicts of interest. Dr Berlin Kafoa, Director, Public Health Division at The Pacific Community (SPC), comments: What is the immediate threat posed by dengue in the Pacific region, and how is this changing? ' 1. Increasing morbidity due to escalating dengue outbreaks reported across the Pacific region with circulation of multiple serotypes. 'Dengue is actively circulating in at least six Pacific Island Countries and Territories (PICTs), including Fiji (>8,000 cases, 4 deaths), Tonga (793 cases, 3 deaths), French Polynesia (>2,000 cases), Samoa (110 cases, 1 death), Cook Islands, and Kiribati. Multiple serotypes (DENV-1, DENV-2, DENV-3) are co-circulating, increasing the risk of severe dengue due to secondary infections in populations with partial immunity. ' 2. Changing epidemiology and vulnerable populations 'There is a growing incidence of severe dengue amongst children and youth with no prior dengue exposure. There are older adults coming from areas historically free of dengue. This suggests immunity gaps, but the lack of updated seroprevalence data limits precise risk profiling. ' 3. Climate and mobility as amplifiers 'Climate change and variability (e.g., rainfall, temperature) is expanding mosquito habitats and altering transmission regional and international travel and trade from endemic areas (e.g., Southeast Asia, South America) raises the risk of virus introduction.' What hopes are currently on the horizon for new technologies or programmes to combat the disease? ' 1. A need for collaboration across sectors, agencies, and countries. 'Through the Pacific Public Health Surveillance Network (PPHSN), we are working with WHO and allied members to support countries with preparedness, detection and response to dengue and other arboviral diseases. This includes: Rapid risk assessments and technical guidance Laboratory supplies and testing algorithms and Strengthening PCR testing capabilities in countries. Subtyping and WGS/Whole-Genome Sequencing via reference labs (e.g., VIDRL in Australia). Dissemination of risk communication messages through multiple channels and sharing of best practices in risk communication and community engagement ' 2. A need for predictive analytics and early warning 'We are exploring predictive algorithms that integrate climate data (e.g., rainfall, temperature), flight and mobility data, and historical outbreak and seroprevalence data. These tools aim to forecast outbreak risks and optimize vector control timing.' ' 3. Vector control capacity building to promote a One Health approach. 'The Pacific Vector Network (PVN) launched in 2023, a service arm of PPHSN, supports a coordinated response to control of vector-borne disease in the region; practical entomology training for PICTs; mosquito surveys, mapping, and surveillance; and provision of vector control equipment and insecticides.' ' 4. New tools being tested 'Other new tools being tested in the region include pilot testing of new technologies such as Sterile Insect Technique (SIT) in French Polynesia, and trials of Wolbachia introduction in Fiji, Vanuatu, New Caledonia, and Kiribati. For possible consideration, there is the introduction of dengue vaccines-contingent on availability of sero-prevalence data.' What is your biggest concern and/or is there anything you wish people understood better? 'The real risk of severe dengue is rising. Severe cases and fatalities are being reported, especially among youth. Dengue should not be dismissed as a mild illness, it can be life-threatening. 'There are gaps in immunity and surveillance. Many populations remain immunologically naive due to limited past exposure. Inadequate seroprevalence data and diagnostic capacity hinder targeted responses. 'There are changes in vector behaviours with possible increase in behaviours resistance to insecticides. 'Dengue is not the only arboviral threat which further complicates surveillance, diagnosis, and response efforts. Other threats include: Zika: Imported cases have been reported in the Pacific Rim (e.g., New Zealand from Fiji). Chikungunya: A major outbreak in La Réunion (339,000+ cases) and an imported case in Wallis and Futuna. Yellow fever: While not yet reported in the Pacific, the presence of Aedes vectors makes introduction a real risk 'There is a need to support the Pacific to acquire new technology for genomic surveillance. Genetic sequencing of dengue strains is essential to track virus movement and mutations across the region, but capacity remains limited. 'Dengue is no longer a seasonal or isolated threat in the Pacific; it is a regional health emergency shaped by climate, mobility, and historical vulnerabilities. Through a One Health multisector, multiagency and multi-country collaborative efforts with WHO, PIHOA and PPHSN partners, we are responding and building the tools and intelligence to predict, prepare and hopefully prevent the next wave.'


Scoop
3 days ago
- Scoop
Dengue In The Pacific Region – Expert Q&A
The Cook Islands declared a dengue outbreak in Rarotonga last week. Other Pacific nations including Sāmoa, Tonga, and Fiji are also experiencing outbreaks. The SMC asked experts about the current situation in the Pacific. Dr Gregor Devine, Senior Director, Field Entomology at the World Mosquito Program, comments: What is the immediate threat posed by dengue in the wider Pacific region, and how is this changing? 'Dengue fever is the world's most prevalent disease spread by mosquitoes. Cases are increasing across the Western Pacific (e.g., Pacific Island Countries and Territories, Laos, Cambodia, Vietnam) and South East Asia (e.g., Bangladesh, Indonesia, Thailand, and Timor-Leste). All of these countries experienced significant dengue outbreaks in 2024 and 2025, and the general trend in cases globally is relentlessly upwards. 'These increases are fuelled by 1) climate change (increased temperatures encourage mosquito proliferation and shorten the time needed for viruses to replicate in their mosquito hosts), 2) increasing globalisation (and the increased movement of humans carrying the virus), 3) immunological naïveté, where human populations are being exposed to new dengue serotypes, and 4) the limited impact of existing control measures. 'According to the Pacific Syndromic Surveillance System, as of May 27th 2025, dengue cases are increasing or peaking in Fiji, Samoa, Tonga, Kiribati, and Cook Islands. There have been deaths reported from Fiji, Tonga and Samoa.' What hopes are currently on the horizon for new technologies or programmes to combat the disease? 'Current responses to dengue outbreaks largely involve the application of insecticides and the implementation of environmental 'clean-up' campaigns, but these have limited impacts. Moreover, resistance to insecticides is increasingly documented in the Pacific, and this further reduces the impact of conventional vector control. 'A safe, effective and sustainable solution exists. The Wolbachia method, developed by the non-profit World Mosquito Program, involves releasing mosquitoes infected with a bacteria that reduces their ability to transmit dengue. It has been proven to have a tremendous impact on dengue transmission around the world. Wolbachia releases have been piloted in Fiji, Vanuatu, Kiribati, and New Caledonia. Following six years of Wolbachia mosquito releases in New Caledonia, the project has been hailed a monumental success, and the French territory hasn't had a dengue epidemic since 2019. This year, releases will continue in Kiribati, and be adopted in Timor-Leste.' What is your biggest concern and/or is there anything you wish people understood better about the situation? 'The upward trend in dengue case numbers regionally will inevitably stress public health systems and impact family well-being (through both the health and economic costs of hospitalisation and the lost earnings of the sick). Sustainable ways to combat dengue, such as the Wolbachia method, are desperately needed. Vaccines are still years away from being universally affordable and applicable.' Dr Joan Ingram, Medical Advisor, Immunisation Advisory Centre, comments: What is the immediate threat posed by dengue in the Pacific region, and how is this changing? 'Dengue outbreaks are currently affecting Kiribati, Samoa, Fiji, Tonga and French Polynesia with the most cases being reported from Fiji, according to The Pacific Community (SPC). Case numbers are increasing in all of those areas, apart from in French Polynesia. There are four dengue serotypes – and both serotype 1 and serotype 2 are currently circulating. 'The Pacific Islands are vulnerable to dengue outbreaks as they have high levels of mosquitoes and dengue viruses can be introduced by infected people. 'Between 2012 and 2021, there were 69 outbreaks of dengue fever among the Pacific Islands. However, they are not unique in having dengue fever – dengue is common in many other regions including the Americas, Africa, the Middle East and Asia. 'Globally, dengue cases were at a very high level in 2024, particularly in South America. Cases increased almost 30-fold there between 2000 and 2024. Urbanisation, globalisation and climate change have contributed to this increase.' What is your biggest concern and is there anything you wish people understood better about the situation? 'Dengue is often a leading cause of fever in risk countries. Estimates are that around 6 in 1000 travellers spending a month in a risk area become unwell with dengue, with up to 30% of them being hospitalised. 'Dengue is spread by common biting mosquitoes (various Aedes species), which thrive where humans live. The main way to avoid dengue is mosquito bite avoidance. Aedes mosquitoes (unlike the malaria-transmitting Anopheles) are daytime feeders, with two peak times of biting activity in the day – 2 to 3 hours after dawn, and mid-to-late afternoon. However, they may feed all day indoors or on overcast days. 'People should regularly apply effective repellent as well as using light-coloured clothing to cover up. In addition, they should take steps to reduce mosquitoes indoors (such as screens on windows and doors), and in the environment by emptying any water-holding containers.' What hopes are currently on the horizon for new technologies or programmes to combat the disease? 'Qdenga, a dengue vaccine, is available in 30 countries overseas but not in New Zealand. It protects against dengue serotype 1 and 2 very well, especially in people who have had previous dengue. Protection against serotypes 3 and 4 is still being evaluated. 'An earlier dengue vaccine increased the risk of severe dengue in people who had not had dengue previously. It does not seem as though Qdenga does that, but it is still being monitored and most authorities prefer to administer it to people with past dengue infection although the guidelines differ. 'A new hope for the future is the use of Wolbachia-infected Aedes aegypti. Wolbachia infection blocks the transmission of the dengue virus from mosquitoes. Trials are ongoing with promising results.' No conflicts of interest. Dr Berlin Kafoa, Director, Public Health Division at The Pacific Community (SPC), comments: What is the immediate threat posed by dengue in the Pacific region, and how is this changing? ' 1. Increasing morbidity due to escalating dengue outbreaks reported across the Pacific region with circulation of multiple serotypes. 'Dengue is actively circulating in at least six Pacific Island Countries and Territories (PICTs), including Fiji (>8,000 cases, 4 deaths), Tonga (793 cases, 3 deaths), French Polynesia (>2,000 cases), Samoa (110 cases, 1 death), Cook Islands, and Kiribati. Multiple serotypes (DENV-1, DENV-2, DENV-3) are co-circulating, increasing the risk of severe dengue due to secondary infections in populations with partial immunity. ' 2. Changing epidemiology and vulnerable populations 'There is a growing incidence of severe dengue amongst children and youth with no prior dengue exposure. There are older adults coming from areas historically free of dengue. This suggests immunity gaps, but the lack of updated seroprevalence data limits precise risk profiling. ' 3. Climate and mobility as amplifiers 'Climate change and variability (e.g., rainfall, temperature) is expanding mosquito habitats and altering transmission regional and international travel and trade from endemic areas (e.g., Southeast Asia, South America) raises the risk of virus introduction.' What hopes are currently on the horizon for new technologies or programmes to combat the disease? ' 1. A need for collaboration across sectors, agencies, and countries. 'Through the Pacific Public Health Surveillance Network (PPHSN), we are working with WHO and allied members to support countries with preparedness, detection and response to dengue and other arboviral diseases. This includes: Rapid risk assessments and technical guidance Laboratory supplies and testing algorithms and Strengthening PCR testing capabilities in countries. Subtyping and WGS/Whole-Genome Sequencing via reference labs (e.g., VIDRL in Australia). Dissemination of risk communication messages through multiple channels and sharing of best practices in risk communication and community engagement ' 2. A need for predictive analytics and early warning 'We are exploring predictive algorithms that integrate climate data (e.g., rainfall, temperature), flight and mobility data, and historical outbreak and seroprevalence data. These tools aim to forecast outbreak risks and optimize vector control timing.' ' 3. Vector control capacity building to promote a One Health approach. 'The Pacific Vector Network (PVN) launched in 2023, a service arm of PPHSN, supports a coordinated response to control of vector-borne disease in the region; practical entomology training for PICTs; mosquito surveys, mapping, and surveillance; and provision of vector control equipment and insecticides.' ' 4. New tools being tested 'Other new tools being tested in the region include pilot testing of new technologies such as Sterile Insect Technique (SIT) in French Polynesia, and trials of Wolbachia introduction in Fiji, Vanuatu, New Caledonia, and Kiribati. For possible consideration, there is the introduction of dengue vaccines-contingent on availability of sero-prevalence data.' What is your biggest concern and/or is there anything you wish people understood better? 'The real risk of severe dengue is rising. Severe cases and fatalities are being reported, especially among youth. Dengue should not be dismissed as a mild illness, it can be life-threatening. 'There are gaps in immunity and surveillance. Many populations remain immunologically naive due to limited past exposure. Inadequate seroprevalence data and diagnostic capacity hinder targeted responses. 'There are changes in vector behaviours with possible increase in behaviours resistance to insecticides. 'Dengue is not the only arboviral threat which further complicates surveillance, diagnosis, and response efforts. Other threats include: Zika: Imported cases have been reported in the Pacific Rim (e.g., New Zealand from Fiji). Chikungunya: A major outbreak in La Réunion (339,000+ cases) and an imported case in Wallis and Futuna. Yellow fever: While not yet reported in the Pacific, the presence of Aedes vectors makes introduction a real risk 'There is a need to support the Pacific to acquire new technology for genomic surveillance. Genetic sequencing of dengue strains is essential to track virus movement and mutations across the region, but capacity remains limited. 'Dengue is no longer a seasonal or isolated threat in the Pacific; it is a regional health emergency shaped by climate, mobility, and historical vulnerabilities. Through a One Health multisector, multiagency and multi-country collaborative efforts with WHO, PIHOA and PPHSN partners, we are responding and building the tools and intelligence to predict, prepare and hopefully prevent the next wave.'